Status:
COMPLETED
Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis
Lead Sponsor:
Anterios Inc.
Conditions:
Primary Axillary Hyperhidrosis
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to confirm the effect of ANT-1403 in the treatment of primary axillary hyperhidrosis.
Eligibility Criteria
Inclusion
- ages 18 - 70 years of age
- diagnosis of moderate to severe primary axillary hyperhidrosis
- ≥50 mg of sweat production/axilla in 5 minutes as measured gravimetrically
- HDSS score of ≥3
Exclusion
- diagnosis of secondary hyperhidrosis
- skin affliction in the axilla requiring medical treatment
- 20% aluminum hydrochloride, e.g. Drysol®, in 2 weeks prior of Baseline
- oral anticholinergic treatment
- botulinum toxin treatment in the prior 9 months
- history of surgery for axillary hyperhidrosis
- present or history of neuromuscular disease
- female subjects who are pregnant or are nursing a child
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT01799824
Start Date
February 1 2013
End Date
July 1 2013
Last Update
December 10 2013
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Miami, Florida, United States, 33137
2
Pinellas Park, Florida, United States, 33781
3
West Palm Beach, Florida, United States, 33401
4
Louisville, Kentucky, United States, 40202